Compare AbCellera Biologics Inc (ABCL) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs General Mills, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while General Mills, Inc. trades at $36.54 (market cap $19.80B). The key difference: General Mills, Inc. is far larger — about 8.4× AbCellera Biologics Inc's market cap, and General Mills, Inc. pays a 6.58% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GIS | |
|---|---|---|
Market Cap | $2.35B | $19.80B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $51.84 |
52-Week Low | $2.78 | $32.17 |
Enterprise Value | $1.99B | $33.29B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
General Mills (GIS) trades at $37.10, down 1.25% on the day, with a bullish technical signal from moving averages and a neutral RSI near 58. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. The company maintains a dividend of $0.61 per share and is implementing cost-saving initiatives targeting $3B by 2030 to counter margin pressures from private-label competition.
Outlook: GIS presents a value opportunity with a low P/E of 9.23, but faces headwinds from sluggish sales and negative net income margin. Risks include consumer spending shifts and high debt levels. Analyst consensus is cautious with a hold-heavy rating and a $36.14 price target slightly below current levels, suggesting limited near-term upside without stronger earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
